
CareDx Comments on Issuance of Proposed LCD for Molecular Testing for Solid Allograft Rejection
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today commented on the issuance of proposed changes to the Local Coverage…












